Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- PLAB +16.6%, NUAN +9.4%, OOMA +5%, ATKR +4.4%, XCRA +3.6%, MRVL +2.7%, MCHP +0.5%
M&A news:
- MLNT +7.7% (to acquire the infectious disease business from The Medicines Company (MDCO) for $270 million in upfront consideration and guaranteed payments)
- RGC +5.6% (Regal Entertainment confirms Cineworld Group plc discussions about possible all-cash acquisition of Regal at $23.00 per share), AMC +1.9%
Other news:
- CAPR +29.2% (FDA has cleared its IND for a new clinical trial of CAP-1002)
- NLST +21.2% (U.S. International Trade Commission votes to institute an investigation of certain memory modules and components thereof)
- SEED +21% (Origin Agritech and KWS SAAT SE enter into commercial license and collaboration agreement)
- MARA +18.4% (after closing down ~40%)
- RXII +16.4% (announces results of a consumer/functional testing program with RXI-231)
- PETX +12.1% (terminates stock offering (per Nov 27 announcement))
- DPW +10.9% (after closing down nearly 40%)
- TEUM +7.6% (continued volatility)
- IDRA +7.4% (FDA has granted Fast Track designation for the company's lead development candidate IMO-2125 in combination with Ipilimumab)
- OVID +6.4% (announces OV101 shows comparable PK profile in Ph 1 study of adolescent patients; now anticipates data from the STARS trial to be available in the second half of 2018)
- CMG +3.5% (launches search to identify a new CEO; Founder Steve Ells to transition to Executive Chairman; provides Q4 comp guidance)
- PSTI +2% (announces publication of preclinical findings from its PLX-PAD studies in journal Cytotherapy), .
Analyst comments:
- MULE +3.8% (upgraded to Outperform from Perform at Oppenheimer)
- DPZ +1.9% (upgraded to Buy from Neutral at Nomura)
- AGN +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ZTS +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CHD +0.8% (upgraded to Buy from Hold at Societe Generale)